Authors


Richard J. Tinsley, Putnam Associates

Latest:

How to Think About Companion Diagnostics

Both promise and peril exist for drugmakers in working with diagnostic tests to commercialize new medications or refine the applicability of existing ones


By Alan Kennedy, Executive Director, Team-Up

Latest:

A new approach to pharma supply-chain collaboration

Team-Up seeks to bring manufacturers and logistics providers together


Michael Bonney, CEO, Cubist Pharmaceuticals

Latest:

Bringing New Science, and New Partners, Into the Drug Development Process

Today’s evolving healthcare environment calls for more collaboration in bringing drugs to market


Peter Gilmore, KPMG LLP

Latest:

Ten integrated imperatives for pharma commercial transformation

The pharma industry needs to go farther in adapting to new marketplace realities



Edgar Adams, ScD, Robin Carter, Heather Raschtschenia

Latest:

Economic Considerations For REMS

Drug sponsors have options in both how the new FDA risk programs are structured and how to execute them


Renee Selman, Adheris Health

Latest:

Improving health outcomes through customized adherence messages

Optimized multichannel communications will prevent illness and save lives



Michael Steiner, RegentAtlantic Capital

Latest:

Is There Life After the Lab?

Today’s uncertain work environment obliges you to manage your career and financial status to keep your options open


By Ben Curtis

Latest:

Future look: The Impact of Biosimilars on Oncology

Marketing strategies will adjust with the advent of biosimilars


Jeffrey Borman, Integrichain, Inc.

Latest:

Forecasting Returns When Patents Expire

Overestimating product reserves as loss of exclusivity (LoE) approaches can be a $75-million mistake


Joel Wayment, Cardinal Health 3PL Services

Latest:

CAR-T Therapies: Three Supply Chain Considerations

As more of these novel—and costly—cell therapies gain approval, revamped strategies around scaling, coordination and workflow are critical to their launch


Personal Care Logistics Conference, Inc.

Latest:

HPCLC Spring Meeting recap

Logistics managers in life sciences and personal care focus on transportation capacity


Rick Moore, Compliance Implementation Services

Latest:

Lessons learned on bona fide service fees and fair market value-is there a 'right answer'?

Recent regulatory actions and court cases highlight the importance of due diligence in reporting the value of service fees when federal reimbursements are concerned. The financial consequences can be substantial



Matt Wllach, Veeva Systems

Latest:

True Software-as-a-Service (SaaS) Transforms Sales Automation Systems to Make Upgrades Painless

Multi-tenant sales-force automation (SFA) systems are coping with an increasingly complex regulatory environment


Lena Anthony, contributing editor

Latest:

In an EHR era, adverse event reporting takes on a new look

As the number of adverse events (AEs) grows year by year, regulators and industry managers are looking at automated systems to handle the burden


Ricahrd Pazdur, MD, FDA

Latest:

Cancer care in the US -- looking back, looking forward

Begin thinking of your business as a 'disease' company vs. a 'drug' company


Ben Johnson

Latest:

Supporting pharma’s shift in focus from patient 'outputs’ to ‘outcomes’

The rise of the patient voice and increased acceptance of remote engagement are sparking a culture change across the supply chain


Frank Gallo

Latest:

The dynamic evolution of multi-sponsor REMS

Risk Evaluation & Mitigation Strategy (REMS) programs are evolving, with new complexities for compliance managers


Jim Hollingshead, Deloitte Consulting LLP

Latest:

The stakes are high in the debate over follow-on biologics

Could proposed legislation undercut the promise of targeted therapies?



Sven Lee, Catalent Pharma Solutions

Latest:

Biosimilars: It's a matter of time

For global markets, there is a need to balance the imperative to get to market quickly against the evolving regulatory landscape



Ed Doran, IntegriChain

Latest:

Strategies for effective patient services programs

Addressing continued hurdles in patient adherence


Jeff Baker, Noble Rx Marketing

Latest:

The power of visualization in patient education

Visual aids, diminished for a time as a marketing and educational tool because of industry restrictions, are making a comeback


Arun Shastri

Latest:

Artificial Intelligence: Beyond the glamor

It takes gritty work to make an AI application succeed—but it can be worth the effort


David L. Knowlton, HealthWell Foundation

Latest:

Coverage -- Access: Pharma Must Play Activist Role in Health Reform Efforts

Private and public sectors can collaborate to achieve meaningful reform


Hussain Mooraj, AMR Research

Latest:

Biopharma Sales and Marketing Process Changes Are Failing to Keep up With Industry Evolution

Better internal collaboration within companies is critical to improving the vital physician-rep relationship


Nareda Mills, Ashfield U.S.A

Latest:

Rare disease patient support

Rare diseases are hard to treat; supporting the patient can be even more challenging

© 2025 MJH Life Sciences

All rights reserved.